JP2022549272A5 - - Google Patents
Info
- Publication number
- JP2022549272A5 JP2022549272A5 JP2022518263A JP2022518263A JP2022549272A5 JP 2022549272 A5 JP2022549272 A5 JP 2022549272A5 JP 2022518263 A JP2022518263 A JP 2022518263A JP 2022518263 A JP2022518263 A JP 2022518263A JP 2022549272 A5 JP2022549272 A5 JP 2022549272A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- pharmaceutically acceptable
- acceptable salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962904567P | 2019-09-23 | 2019-09-23 | |
| US62/904,567 | 2019-09-23 | ||
| PCT/US2020/052096 WO2021061695A1 (en) | 2019-09-23 | 2020-09-23 | Treatment of egfr mutant-related cancers using a combination of egfr and cdk4/6 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022549272A JP2022549272A (ja) | 2022-11-24 |
| JP2022549272A5 true JP2022549272A5 (https=) | 2023-10-02 |
Family
ID=75166417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022518263A Pending JP2022549272A (ja) | 2019-09-23 | 2020-09-23 | Ｅｇｆｒ阻害剤とｃｄｋ４／６阻害剤の組み合わせを用いたｅｇｆｒ変異に関連する癌の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12390464B2 (https=) |
| EP (1) | EP4034121A4 (https=) |
| JP (1) | JP2022549272A (https=) |
| CN (1) | CN114430681A (https=) |
| AU (1) | AU2020352528A1 (https=) |
| TW (1) | TW202126305A (https=) |
| WO (1) | WO2021061695A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220079944A1 (en) * | 2019-01-29 | 2022-03-17 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2954298A1 (en) * | 2014-07-24 | 2016-01-28 | Beta Pharma, Inc. | 2-h-indazole derivatives as cyclin-dependent kinase (cdk) inhibitors and therapeutic uses thereof |
| CN105085489B (zh) | 2014-11-05 | 2019-03-01 | 益方生物科技（上海）有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
| JP6709786B2 (ja) * | 2014-12-11 | 2020-06-17 | ベータ ファーマ，インコーポレイテッド | Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体 |
| US20190275049A1 (en) * | 2016-11-16 | 2019-09-12 | Pfizer Inc. | Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer |
| EP3585389A4 (en) * | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
-
2020
- 2020-09-23 CN CN202080066624.7A patent/CN114430681A/zh active Pending
- 2020-09-23 WO PCT/US2020/052096 patent/WO2021061695A1/en not_active Ceased
- 2020-09-23 TW TW109132919A patent/TW202126305A/zh unknown
- 2020-09-23 AU AU2020352528A patent/AU2020352528A1/en active Pending
- 2020-09-23 EP EP20868541.2A patent/EP4034121A4/en active Pending
- 2020-09-23 JP JP2022518263A patent/JP2022549272A/ja active Pending
- 2020-09-23 US US17/641,868 patent/US12390464B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101316590B (zh) | 血管生成抑制剂和c-kit激酶抑制剂的组合使用 | |
| JP5522371B2 (ja) | 化合物とその製造方法、および医薬組成物 | |
| CN113474337A (zh) | 作为fgfr抑制剂用于治疗癌症的7-((3，5-二甲氧基苯基)氨基)喹喔啉衍生物 | |
| CN108366992A (zh) | 蛋白水解靶向嵌合体化合物及其制备和应用方法 | |
| CN114732910B (zh) | P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd | |
| JP2019518765A5 (https=) | ||
| JP2019011375A5 (https=) | ||
| RU2006121337A (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| JP2023504230A (ja) | Ｐｒｍｔ５阻害剤の組合せ医薬 | |
| JP2020531447A5 (https=) | ||
| JP2012515787A5 (https=) | ||
| HRP20220619T1 (hr) | Postupci za liječenje ar+ raka dojke | |
| RU2020142739A (ru) | Ингибиторы mdm2 и их комбинации | |
| KR20140025434A (ko) | Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법 | |
| CA2683641A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
| KR20160005341A (ko) | Ampk 활성인자 및 세로토닌성 제제를 포함하는 약학 조성물 및 이의 사용 방법 | |
| WO2015154725A1 (zh) | 喹唑啉衍生物及其制备方法和在医药上的应用 | |
| CN110072528A (zh) | 治疗肿瘤的药物组合物 | |
| KR20190132687A (ko) | 항암 조합 요법 | |
| JPWO2021060453A5 (https=) | ||
| JP2018509442A (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| JP2017501983A5 (https=) | ||
| JP2010534219A (ja) | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患の処置のための、イミダゾキノリンの使用 | |
| WO2019224774A1 (en) | Heterocyclic amides as rip1 kinase inhibitors | |
| Konar et al. | Synthesis and clinical development of palbociclib: An overview |